CK19和BCL-2以及MYC基因mRNA联合检测对乳腺癌诊断的临床应用研究

摘要

Objective:To evaluate the clinical application of MYC,BCL -2 and CK19 gene in the diagnosis of breast cancer by combined detection. Methods: MYC,BCL -2 and CK19 in the samples of 34 health women,55 patients with benign breast disease and 91 patients with breast cancer were detected by FQ - PCR. β2 - microglobin was used as internal control. Results; MYC,BCL -2 and CK19/β2 - microglobin in breast cancer group were higher than those in health women and patients with benign breast disease groups( P <0.05). There were no significant difference in MYC,BCL-2 and CK19/β2 -microglobin between normal controls and benign breast disease group(P >0. 05). There were no difference in β2 - microglobin among three groups (P > 0. 05). The sensitivity of MYC, BCL - 2 and CK19 gene express by combined detection was higher than that of single gene detection. Conclusion: FQ - PCR is a rapid method for quantitating MYC, BCL - 2 and CK19. The combined detection can improve the sensitivity of diagnosis in breast cancer.%目的:探讨核内原癌基因(nuclear oncogene,MYC)和B细胞淋巴瘤/白血病-2基因(B cell lymphoma/leukemia 2 gene,BCL-2)与细胞角蛋白19(nuclear oncogene,CK19)基因表达水平在乳腺癌诊断和治疗监测中的应用.方法:建立荧光定量聚合酶链反应(FQ-PCR)法,并以GAPDH为内对照测定34名健康女性体检者、55例良性乳腺疾病患者和91例乳腺癌患者外周血中MYC,BCL-2和CK19的表达量.结果:MYC,BCL-2和CK19表达水平与GAPDH的比值在乳腺癌组显著高于健康女性体检者和良性乳腺疾病患者(P＜0.05),它们在正常对照组和良性乳腺疾病组间差异无统计学意义(P＞0.05),3组GAPDH差异无统计学意义(P＞0.05)；MYC,BCL-2与CK19联合检测的灵敏度高于单个基因的检测.结论:FQ-PCR技术可以快速定量检测MYC,BCL-2和CK19 mRNA,三者联合检测可有效提高对乳腺癌诊断的灵敏度.